Our work on inhaled powder formulation of tamibarotene, a repurposed drug that exhibits broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV and influenza A H1N1 virus following pulmonary delivery, is accepted for publication in Advanced Therapeutics. This work is in collaboration with Dr. Shuofeng Yuan from the HKU Department of Microbiology.
Congrats to Rachel, Carol, Han Cong, Rico, Zitong and the team!
Comments